Filing Analysis
Inmune Bio held its annual meeting of stockholders on June 16, 2026, where shareholders approved the Third Amended and Restated 2021 Stock Incentive Plan and the election of directors.
🚩 Red Flags
- The approval of an evergreen provision and the increase in the share pool can lead to significant equity dilution for existing shareholders over the 2027-2031 period.
📋 Key Facts
- The 2021 Stock Incentive Plan share pool was increased from 6,500,000 to 9,158,525 shares.
- An 'evergreen provision' was approved, allowing automatic annual increases from 2027 through 2031 by the lesser of 10% of outstanding shares or a smaller amount determined by the board.
- CBIZ CPAs P.C. was ratified as the independent auditor for the fiscal year ending December 31, 2026.
- Directors David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda, and Marcia Allen were elected.
- As of April 20, 2026, there were 26,585,258 shares of common stock outstanding.
Inmune Bio, Inc. issued a press release on June 2, 2026, announcing exploratory chi-separation (χ-separation) MRI imaging analysis results from the MINDFuL Phase 2 clinical trial of XPro™ (XPro1595) for early Alzheimer's disease.
📋 Key Facts
- The filing reports results from the MINDFuL Phase 2 clinical trial.
- The trial focuses on XPro™ (XPro1595) for patients with early Alzheimer's disease, including mild cognitive impairment (MCI) and mild Alzheimer’s disease dementia.
- The specific data released pertains to exploratory chi-separation (χ-separation) MRI imaging analyses.
Inmune Bio announced that the U.S. FDA has granted Fast Track designation to its drug candidate XPro™ (pegipanermin) for the treatment of early Alzheimer's disease. This designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
📋 Key Facts
- On May 14, 2026, the FDA granted Fast Track designation to XPro™ (pegipanermin).
- XPro™ is described as a first-in-class selective soluble TNF inhibitor.
- The target indication for the Fast Track designation is early Alzheimer's disease (AD).
- The announcement was disclosed under Item 8.01 (Other Events) and included the press release as Exhibit 99.1.
INmune Bio Inc. entered into an amended and restated license agreement with Anthony Nolan to secure the long-term supply of umbilical cord tissue for its CORDStrom™ platform. The parent company is now a direct party to the agreement, assuming joint liability for payment obligations including a 2% royalty on net sales.
📋 Key Facts
- The agreement was signed on April 29, 2026, amending a previous 2017 agreement between the subsidiary IMB and Anthony Nolan.
- INmune Bio Inc. (the parent) is now a party to the agreement and jointly liable for royalty payments.
- The royalty is set at 2% of net sales of products, capped at an annual maximum of £5,000,000.
- Service fees for umbilical cord tissue are £400 plus VAT, with annual CPI-linked increases starting January 1, 2027.
- The agreement term extends to 10 years from the date of the first commercial sale.
- The company can terminate the agreement with 30 days' notice, while Anthony Nolan requires 6 months' notice.
Inmune Bio, Inc. has furnished an updated investor presentation slide deck to be used in upcoming presentations. The filing is a standard Regulation FD disclosure and does not report any material changes to the company's operations or financial status.
📋 Key Facts
- The company filed the 8-K on February 27, 2026.
- The filing includes Item 7.01 (Regulation FD Disclosure).
- Exhibit 99.1 contains the new Investor Presentation.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
INmune Bio announced it will host a webinar on February 27, 2026, to discuss the registrational pathway for its drug candidate XPro1595 (XPro™) in the treatment of early Alzheimer’s disease.
📋 Key Facts
- The webinar is scheduled for February 27, 2026, at 9:30 a.m. ET.
- The presentation will focus on the registrational pathway for XPro1595.
- The target indication for the drug candidate is early Alzheimer’s disease.
- The announcement was made via a press release attached as Exhibit 99.1.
Inmune Bio, Inc. filed an 8-K under Item 8.01 (Other Events) to announce a webinar on its CORDStrom therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), scheduled for February 26, 2026. This is a routine informational filing with no material financial or corporate governance implications.
📋 Key Facts
- Company will host a webinar on CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET
- Filing signed by CEO David Moss on February 19, 2026
- Company is listed on NASDAQ under ticker INMB, common stock par value $0.001 per share
- Company is incorporated in Nevada with principal offices in Boca Raton, Florida
- Company is NOT classified as an emerging growth company
- Press release attached as Exhibit 99.1